As the number of specialised gene therapies continues to grow in the biotech sector, one particular subtype— those using adeno-associated virus (AAV) vectors—is becoming increasingly popular. In this month’s cover story we investigate several high-profile gene therapies that use these AAV vectors that are expected to be in the news in 2024.

Additionally, on the occasion of World TB Day, observed on 24 March, we take the opportunity to look at the need for new alternatives to treat HIV-TB coinfections. While several options are explored, experts say the landscape is alarmingly sparse.

Also in this issue, a freewheeling interview with the head of the Digital Therapeutics Alliance, explores the state of digital therapeutics—their development and use in the broader healthcare context. Don’t miss additional features on the growing role of patient advocacy organisations and priority review vouchers

All this and the latest news and analysis on the pharmaceutical and biotech industry.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.